Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Oct;101(4):556-565. doi: 10.1111/ejh.13147. Epub 2018 Sep 5.

PMID:
30027641
2.

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.

Lund J, Gruber A, Lauri B, Duru AD, Blimark C, Swedin A, Hansson M, Forsberg K, Ahlberg L, Carlsson C, Waage A, Gimsing P, Vangsted AJ, Frølund U, Holmberg E, Gahrton G, Alici E, Hardling M, Mellqvist UH, Nahi H.

Cancer Med. 2018 Jun;7(6):2256-2268. doi: 10.1002/cam4.1422. Epub 2018 Apr 19.

3.

Real-world data on first relapse of acute lymphoblastic leukemia in patients >55 years.

Lennmyr EB, Kozlowski P, Ahlberg L, Bernell P, Hulegårdh E, Izarra AS, Karlsson K, Tomaszewska-Toporska B, Åström M, Hallböök H; Swedish Adult Acute Lymphoblastic Leukemia Group, SVALL.

Leuk Lymphoma. 2018 Oct;59(10):2470-2473. doi: 10.1080/10428194.2017.1416369. Epub 2018 Jan 18. No abstract available.

PMID:
29345172
4.

Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.

Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY; Swedish Myeloma Registry.

Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7.

5.

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.

Jakobsen Falk I, Lund J, Gréen H, Gruber A, Alici E, Lauri B, Blimark C, Mellqvist UH, Swedin A, Forsberg K, Carlsson C, Hardling M, Ahlberg L, Lotfi K, Nahi H.

Cancer Chemother Pharmacol. 2018 Jan;81(1):183-193. doi: 10.1007/s00280-017-3481-8. Epub 2017 Nov 25.

6.

Age but not Philadelphia positivity impairs outcome in older/elderly patients with acute lymphoblastic leukemia in Sweden.

Kozlowski P, Lennmyr E, Ahlberg L, Bernell P, Hulegårdh E, Karbach H, Karlsson K, Tomaszewska-Toporska B, Åström M, Hallböök H; Swedish Adult Acute Lymphoblastic Leukemia Group (SVALL).

Eur J Haematol. 2017 Aug;99(2):141-149. doi: 10.1111/ejh.12896. Epub 2017 Jun 14.

7.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.

Rosengren S, Mellqvist UH, Nahi H, Forsberg K, Lenhoff S, Strömberg O, Ahlberg L, Linder O, Carlson K.

Bone Marrow Transplant. 2016 Dec;51(12):1569-1572. doi: 10.1038/bmt.2016.249. Epub 2016 Oct 3.

PMID:
27694943
8.

N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.

Mylin AK, Goetze JP, Heickendorff L, Ahlberg L, Dahl IM, Abildgaard N, Gimsing P; Nordic Myeloma Study Group.

Biomark Med. 2015;9(7):679-89. doi: 10.2217/bmm.15.35.

PMID:
26174842
9.

Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.

Bergfelt E, Kozlowski P, Ahlberg L, Hulegårdh E, Hägglund H, Karlsson K, Markuszewska-Kuczymska A, Tomaszewska-Toporska B, Smedmyr B, Åström M, Amini RM, Hallböök H.

Med Oncol. 2015 Apr;32(4):135. doi: 10.1007/s12032-015-0582-2. Epub 2015 Mar 22.

PMID:
25796502
10.

Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study.

Hulegårdh E, Hägglund H, Ahlberg L, Karlsson K, Karbach H, Markuszewska A, Persson I, Åström M, Hallböök H.

Med Oncol. 2014 Aug;31(8):66. doi: 10.1007/s12032-014-0066-9. Epub 2014 Jun 26.

PMID:
24965535
11.

High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.

Kozlowski P, Åström M, Ahlberg L, Bernell P, Hulegårdh E, Hägglund H, Karlsson K, Markuszewska-Kuczymska A, Tomaszewska-Toporska B, Smedmyr B, Amini RM, Hallböök H; Swedish Adult ALL Group.

Eur J Haematol. 2014;92(5):377-81. doi: 10.1111/ejh.12269. Epub 2014 Feb 21.

PMID:
24443846
12.

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.

Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N; Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27.

PMID:
23708704
13.

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group.

Blood. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24.

14.

High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.

Kozlowski P, Åström M, Ahlberg L, Bernell P, Hulegårdh E, Hägglund H, Karlsson K, Markuszewska-Kuczymska A, Tomaszewska-Toporska B, Smedmyr B, Hallböök H.

Haematologica. 2012 Sep;97(9):1414-21. doi: 10.3324/haematol.2011.057851. Epub 2012 Apr 17.

15.

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F.

Lancet Oncol. 2010 Oct;11(10):973-82. doi: 10.1016/S1470-2045(10)70198-4.

PMID:
20863761
16.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group.

Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6.

17.

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study.

Hedenus M, Birgegård G, Näsman P, Ahlberg L, Karlsson T, Lauri B, Lundin J, Lärfars G, Osterborg A.

Leukemia. 2007 Apr;21(4):627-32. Epub 2007 Jan 25. Erratum in: Leukemia. 2008 Feb;22(2):462.

PMID:
17252006
18.

Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.

Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wislöff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerström J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL; Nordic Myeloma Study Group.

Haematologica. 2006 Sep;91(9):1228-33.

19.

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A, Boiron JM, Einsele H, Chopra R, Carella A, Cavenagh J, Gratwohl A, Garban F, Zander A, Björkstrand B, Niederwieser D, Gahrton G, Apperley JF; Chromic Leukaemia Working Party of the EBMT.

Blood. 2005 Jun 1;105(11):4532-9. Epub 2005 Feb 24.

20.

Determination of physical property gradients from measured surface wave dispersion.

Tittmann BR, Ahlberg LA, Richardson JM, Thompson RB.

IEEE Trans Ultrason Ferroelectr Freq Control. 1987;34(5):500-7. No abstract available.

PMID:
18291876
21.

A shear wave rheology sensor.

Cohen-Tenoudji F, Pardee WJ, Tittmann BR, Ahlberg LA, Elsley RK.

IEEE Trans Ultrason Ferroelectr Freq Control. 1987;34(2):263-9. No abstract available.

PMID:
18290118

Supplemental Content

Loading ...
Support Center